Snapshot from Aug 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / argenx acquires Forte Biosciences
Business acquisition

argenx acquires Forte Biosciences

Analysis based on 10 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
30
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition strengthens Argenx's immunology pipeline with a promising asset, potentially boosting its long-term growth prospects. Forte Biosciences shares surged over 22% in overnight trading, reflecting investor optimism about the premium offer.

biotechnology pharmaceuticals
Event Summary

Argenx SE, a Dutch immunology company, announced a definitive agreement to acquire Forte Biosciences, Inc. for $77 per share in cash, representing a total equity value of approximately $2.2 billion. The acquisition price reflects an 86% premium to Forte's volume-weighted average price since reporting positive Phase 1b vitiligo data on July 9, 2026. The deal centers on FB102, Forte's lead anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, and potential in alopecia areata and other autoimmune diseases. Argenx will fund the transaction entirely from cash on hand, and it is expected to close in Q3 2026. The boards of both companies have approved the deal. Goldman Sachs International and Freshfields LLP advised Argenx, while Guggenheim Securities and Wilson Sonsini Goodrich & Rosati advised Forte.

Key Actions
90 Forte Biosciences reported positive Phase 1b data
80 Argenx agreed to acquire Forte Biosciences
10 Goldman Sachs served as financial advisor Argenx
10 Freshfields served as legal advisor Argenx
10 Guggenheim Partners acted as manager Forte Biosciences
10 Wilson Sonsini Goodrich & Rosati served as legal counsel Forte Biosciences
Entities Involved
stock
Argenx
Argenx is the acquirer, adding FB102 to its portfolio; the deal is funded from cash on hand and expected to close in Q3 2026.
Importance 100.0 Sentiment 30.0
stock
Forte Biosciences
Forte is being acquired at a significant premium; its lead asset FB102 gains access to Argenx's development and commercial capabilities.
Importance 100.0 Sentiment 80.0
per
Karen Massey
Karen Massey is CEO of Argenx and commented on the strategic fit of the acquisition.
Importance 30.0 Sentiment 0.0
per
Paul A. Wagner
Paul A. Wagner is CEO and Chairperson of Forte Biosciences and expressed confidence in Argenx as a partner.
Importance 30.0 Sentiment 0.0
stock
Goldman Sachs
Goldman Sachs served as exclusive financial advisor to Argenx.
Importance 20.0 Sentiment 0.0
priv
Freshfields
Freshfields served as legal advisor to Argenx.
Importance 20.0 Sentiment 0.0
priv
Guggenheim Partners
Guggenheim Securities served as exclusive financial advisor to Forte Biosciences.
Importance 20.0 Sentiment 0.0
priv
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini served as legal counsel to Forte Biosciences.
Importance 20.0 Sentiment 0.0
Relationships
Goldman Sachs related ↔ Guggenheim Partners
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.